ArticleResearch square2025
"Efficacy of Netrin-1 Primed WJMSCs-Derived Secretome in Promoting Wound Healing: An
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Wound healing is a multifaceted biological process that requires tightly regulated cellular activities, including proliferation, migration, and extracellular matrix remodeling. Mesenchymal stromal cells (MSCs) derived from Wharton's Jelly (WJMSC) have emerged as powerful agents in regenerative medicine, largely attributed to their secretome, a dynamic mixture of bioactive molecules and extracellular vesicles. Recent advancements suggest that priming MSCs can potentiate their secretome's therapeutic efficacy. However, the ability to selectively enhance wound repair mechanisms via tailored priming remains unexplored. In this study, we introduce recombinant netrin-1, a multifunctional guidance cue known for its dual role in angiogenesis and immune modulation, as a novel priming agent for WJMSCs. We demonstrate that netrin-1 priming significantly enriches the WJMSCs secretome, amplifying its regenerative potential. Conditioned media collected post 48 hours of netrin-1 PRIMING markedly enhanced fibroblast proliferation and migration, boosted angiogenic tube formation in HUVECs, and skewed macrophage polarization toward an anti-inflammatory M2 phenotype, required as key processes that orchestrates effective tissue repair. This study clearly establishes for the first time the role of netrin-1 priming in creating a functionally superior WJMSCs secretome that targets multiple facets of wound healing synergistically. Unlike conventional single-factor treatments, this approach leverages the natural versatility of MSC secretome augmented with a well-characterized bioactive cue, offering a sophisticated and cell-free therapeutic avenue. The netrin-1 WJMSC secretome presents a promising platform with translational potential to address complex wound healing challenges, especially chronic and non-healing wounds with persistent inflammation and impaired angiogenesis. Altogether, the N1-primed WJ-MSC secretome represents a promising, cell-free therapeutic strategy for enhancing wound healing and tissue regeneration. Future studies will focus on the development of targeted delivery systems to optimize their therapeutic efficacy in preclinical wound models, paving the way for advanced regenerative medicine interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.